86 related articles for article (PubMed ID: 12447996)
1. Engaged urokinase receptors enhance tumor breast cell migration and invasion by upregulating alpha(v)beta5 vitronectin receptor cell surface expression.
Silvestri I; Longanesi Cattani I; Franco P; Pirozzi G; Botti G; Stoppelli MP; Carriero MV
Int J Cancer; 2002 Dec; 102(6):562-71. PubMed ID: 12447996
[TBL] [Abstract][Full Text] [Related]
2. Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer.
Carriero MV; Del Vecchio S; Capozzoli M; Franco P; Fontana L; Zannetti A; Botti G; D'Aiuto G; Salvatore M; Stoppelli MP
Cancer Res; 1999 Oct; 59(20):5307-14. PubMed ID: 10537314
[TBL] [Abstract][Full Text] [Related]
3. Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma.
Zannetti A; Del Vecchio S; Carriero MV; Fonti R; Franco P; Botti G; D'Aiuto G; Stoppelli MP; Salvatore M
Cancer Res; 2000 Mar; 60(6):1546-51. PubMed ID: 10749121
[TBL] [Abstract][Full Text] [Related]
4. Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies.
Carriero MV; Franco P; Del Vecchio S; Massa O; Botti G; D'Aiuto G; Stoppelli MP; Salvatore M
Cancer Res; 1994 Oct; 54(20):5445-54. PubMed ID: 7923178
[TBL] [Abstract][Full Text] [Related]
5. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
6. Calcitonin receptor-stimulated migration of prostate cancer cells is mediated by urokinase receptor-integrin signaling.
Thomas S; Chiriva-Internati M; Shah GV
Clin Exp Metastasis; 2007; 24(5):363-77. PubMed ID: 17487556
[TBL] [Abstract][Full Text] [Related]
7. Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation.
Tarui T; Akakura N; Majumdar M; Andronicos N; Takagi J; Mazar AP; Bdeir K; Kuo A; Yarovoi SV; Cines DB; Takada Y
Thromb Haemost; 2006 Mar; 95(3):524-34. PubMed ID: 16525582
[TBL] [Abstract][Full Text] [Related]
8. Endothelial cells and normal breast epithelial cells enhance invasion of breast carcinoma cells by CXCR-4-dependent up-regulation of urokinase-type plasminogen activator receptor (uPAR, CD87) expression.
Serratì S; Margheri F; Fibbi G; Di Cara G; Minafra L; Pucci-Minafra I; Liotta F; Annunziato F; Pucci M; Del Rosso M
J Pathol; 2008 Apr; 214(5):545-54. PubMed ID: 18189329
[TBL] [Abstract][Full Text] [Related]
9. Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells.
Nip J; Rabbani SA; Shibata HR; Brodt P
J Clin Invest; 1995 May; 95(5):2096-103. PubMed ID: 7537755
[TBL] [Abstract][Full Text] [Related]
10. Heregulin regulation of urokinase plasminogen activator and its receptor: human breast epithelial cell invasion.
Mazumdar A; Adam L; Boyd D; Kumar R
Cancer Res; 2001 Jan; 61(1):400-5. PubMed ID: 11196194
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
Stillfried GE; Saunders DN; Ranson M
Breast Cancer Res; 2007; 9(1):R14. PubMed ID: 17257442
[TBL] [Abstract][Full Text] [Related]
12. Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.
Albo D; Berger DH; Rothman VL; Tuszynski GP
J Surg Res; 1999 Apr; 82(2):331-8. PubMed ID: 10090848
[TBL] [Abstract][Full Text] [Related]
13. Vitronectin binding to urokinase receptor in human breast cancer.
Carriero MV; Del Vecchio S; Franco P; Potena MI; Chiaradonna F; Botti G; Stoppelli MP; Salvatore M
Clin Cancer Res; 1997 Aug; 3(8):1299-308. PubMed ID: 9815812
[TBL] [Abstract][Full Text] [Related]
14. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of migration and invasion of carcinoma cells by urokinase-derived antagonists of alphavbeta5 integrin activation.
Vocca I; Franco P; Alfano D; Votta G; Carriero MV; Estrada Y; Caputi M; Netti PA; Ossowski L; Stoppelli MP
Int J Cancer; 2009 Jan; 124(2):316-25. PubMed ID: 18844213
[TBL] [Abstract][Full Text] [Related]
17. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
[TBL] [Abstract][Full Text] [Related]
18. Green tea polyphenols modulate secretion of urokinase plasminogen activator (uPA) and inhibit invasive behavior of breast cancer cells.
Slivova V; Zaloga G; DeMichele SJ; Mukerji P; Huang YS; Siddiqui R; Harvey K; Valachovicova T; Sliva D
Nutr Cancer; 2005; 52(1):66-73. PubMed ID: 16091006
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas.
Christensen L; Wiborg Simonsen AC; Heegaard CW; Moestrup SK; Andersen JA; Andreasen PA
Int J Cancer; 1996 May; 66(4):441-52. PubMed ID: 8635858
[TBL] [Abstract][Full Text] [Related]
20. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]